Sheep soluble OX40 Ligand ELISA kit
- Known as:
- Sheep soluble OX40 Ligand Enzyme-linked immunosorbent assay test reagent
- Catalog number:
- e14s0320
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Blue gene shanghai
- Gene target:
- Sheep soluble OX40 Ligand ELISA kit
Related genes to: Sheep soluble OX40 Ligand ELISA kit
- Gene:
- TNFRSF4 NIH gene
- Name:
- TNF receptor superfamily member 4
- Previous symbol:
- TXGP1L
- Synonyms:
- ACT35, OX40, CD134
- Chromosome:
- 1p36.33
- Locus Type:
- gene with protein product
- Date approved:
- 1994-12-15
- Date modifiied:
- 2019-04-23
Related products to: Sheep soluble OX40 Ligand ELISA kit
Human ELC ELISA KIT 96 TEST
OxiSelect In Vitro ROS/RNS Assay Kit (Green Fluorescence), Trial Size
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect Methylglyoxal (MG) Competitive ELISA Kit
OxiSelect TBARS Assay Kit (MDA Quantitation), Trial Size
OxiSelect Total Antioxidant Capacity (TAC) Assay Kit, Trial Size
OxiSelect™ In Vitro ROS RNS Assay Kit (Green Fluorescence), Trial Size&_945;2&_946;1 Integrin Ligand Peptide(1-3)-beta-D-glucan Sandwich ELISA, Double Antibody(1-Kit )11,12-EET DHET Immunoassay Kit(1-Kit )11,12-EET_DHET Immunoassay Kit(1-Kit) 11,12-DHET Immunoassay Kit(1-Kit) 14,15-DHET Human Urine ELISA Kit(1-Kit) 14,15-DHET Hypertension ELISA Kit(1-Kit) 14,15-DHET sEH activity ELISA Kit Related articles to: Sheep soluble OX40 Ligand ELISA kit
- Cardiac allografts show poorer long-term survival and decreased tolerance compared to renal allografts, but the underlying mechanisms remain unclear. - Source: PubMed
Publication date: 2026/06/05
Li PeiyuanChang YuanZhu XiaofeiChen XiaoHua XiumengSheng YixuanZhang NingningZhao QianXing KaiDu XingchaoXu MengdaSong Jiangping - Exploring the targeted regulatory effect of isorhynchophylline on lipopolysaccharide (LPS)-induced acute lung injury (ALI) by constructing a drug delivery system of GEF-modified exosomes derived from M2 macrophages (M2-Exos) loaded with isorhynchophylline (GEF-M2-Exos-IRN; GMI). - Source: PubMed
Publication date: 2026/05/14
Zou Jin-RuYang DanZhang Chuan-MingZhang LuZhang Hao-NanSong MiaoMa Jun-BingYang ZhengQiu Min - Papillary thyroid carcinoma (PTC) is the most prevalent thyroid malignancy and its incidence continues to rise. Although prognosis is generally favorable, overdiagnosis, overtreatment, and occasional lethal complications persist. To clarify the micro-environmental basis of PTC metastasis, we integrated single-cell RNA-seq from tumor (T), peritumoral thyroid (PT) and lymph-node (LN) tissues with bulk transcriptomes. Metastatic (M) and non-metastatic (NM) cases were compared, and machine-learning models were built to predict lymph-node status and outcome. Our atlas delineates highly heterogeneous ecosystems across T, PT and LN samples. Within T/NK lymphocytes, both immune-activating and immune-suppressive subsets coexist; NK and CD4+TNFRSF4 cells were selectively enriched in M tumors, implying heterogeneous anti-tumor responses. Among myeloid cells, a Mac-APOC1 subset displayed tumor-associated macrophage/M2 features, consistent with immune escape and dissemination. Dendritic cells differed markedly in antigen presentation and chemotaxis, while RGS5+ myCAFs, markedly expanded in M samples from T and LN, up-regulated metabolic and ribosomal pathways. Trajectory analysis uncovered dynamic CAF state transitions. Tumor epithelial cells followed multiple developmental branches, with those linked to LN invasion predicting poorer survival. A random-forest classifier achieved 0.98 accuracy for N-stage, and a lasso-Cox signature (C-index > 0.9) robustly stratified survival, underscoring the clinical relevance of the identified genes. Collectively, this work reveals the cellular and functional heterogeneity that drives PTC progression, identifies metastasis-associated subpopulations, and demonstrates the utility of machine learning for precise prediction of lymph-node metastasis and patient prognosis, offering a foundation for tailored therapeutic strategies. - Source: PubMed
Publication date: 2026/05/14
An HaoyuanZhang WeishiNiu HengqiLiang WeiliLv BinWu ShihaoXu LiqiangLi WeiGao Shuai - Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by joint inflammation and destruction. Identifying novel therapeutic targets is crucial for improving RA treatment. This study aimed to identify immune-related biomarkers in RA and investigate the potential of CD27 as a therapeutic target. We employed bioinformatics analysis of gene expression data from RA patients and healthy controls (GSE55457), followed by machine learning approaches (LASSO regression and Boruta algorithm) to identify potential biomarkers. Findings were validated in an independent dataset (GSE55235). The therapeutic potential of CD27 neutralization was evaluated in a collagen-induced arthritis (CIA) mouse model. Mechanisms were explored through quantitative real-time PCR, Western blot analysis, ELISA, and flow cytometry to assess T cell subsets, cytokine profiles, and signaling pathways. Bioinformatics analysis identified 714 differentially expressed genes, and machine learning analyses identified CD27, CD24, TNFRSF4, and PDCD1LG2 as potential RA biomarkers, all demonstrating strong diagnostic performance. CD27 showed significant positive correlations with T lymphocyte infiltration. In the CIA model, CD27 neutralization significantly reduced arthritis severity scores. This therapeutic effect was associated with suppression of Th1 responses, evidenced by significantly decreased serum levels of Th1 cytokines (IFN-γ, IL-2, TNF-α) and reduced CD4 + IFN-γ + cell populations, while Th2-related cytokines (IL-4, IL-5) remained largely unaffected. Mechanistically, CD27 neutralization attenuated phosphorylation of AKT and NF-κB p65 in vivo, while p38 MAPK remained unchanged. In vitro, recombinant CD27 protein stimulation of naive CD4 + T cells promoted Th1-biased differentiation, increasing CD4 + IFN-γ + cells and enhancing the phosphorylation of NF-κB p65 and AKT. Our study identifies CD27 as a potential therapeutic target in RA. CD27 neutralization attenuates arthritis severity by suppressing Th1 responses, possibly through modulation of AKT and NF-κB signaling pathways. These findings provide new insights into RA pathogenesis and suggest CD27 as a promising target for RA treatment. - Source: PubMed
Publication date: 2026/04/25
Lu AnghanPu LuqiaoTian YadanSong JiaxinLuo DingxiaWu Jingjin - Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant lung adenocarcinoma (LUAD) typically demonstrates limited response to neoadjuvant immunotherapy (NIT). Elucidating the immune determinants that differentiate responders from non-responders was critical for optimizing immunotherapy strategies. This study aimed to characterize the tumour microenvironment features of KRAS-mutant LUAD following neoadjuvant programmed death protein 1 (PD-1) inhibitor therapy by integrating clinical outcomes with single-cell RNA sequencing (scRNA-seq). - Source: PubMed
Wu SikaiNiu JihengChen XiaoweiLi JinfeiTang QuanyingYang ZhenlinGao Shugeng